The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

More women are recovering and living longer lives due to advancement in breast cancer therapies. Aromatase inhibitors (AIs) are one form of endocrine therapy for breast cancer that may have an impact on the risk of developing cardiovascular diseases later in life. This study investigated whether AI therapy for breast cancer in postmenopausal women increases the risk of developing cardiovascular disease in comparison with tamoxifen therapy or no hormonal therapy.

Methods

Comparisons were made between tamoxifen and no hormonal therapy using PRISMA guidelines. We searched publicly available databases for studies including postmenopausal women who underwent AI therapy for breast cancer investigating the risk ratio of specific cardiovascular outcomes and cardiovascular

SUBMITTER: Berbari E 

PROVIDER: S-EPMC12259065 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature